SCHEDULE 13G: Longitude Capital Discloses 7.3% Passive Stake in CytomX Therapeutics

Longitude Capital Partners V, LLC and its affiliates have reported a passive beneficial ownership of 7.3% in CytomX Therapeutics, Inc., holding 11,538,461 shares of common stock.

Summary

• Longitude Capital Partners V, LLC (LCPV), Longitude Venture Partners V, L.P. (LVPV), Patrick G. Enright, and Juliet Tammenoms Bakker (collectively, the Reporting Persons) have filed a Schedule 13G.
• The filing indicates that the Reporting Persons collectively beneficially own 11,538,461 shares of common stock in CytomX Therapeutics, Inc.
• This ownership represents 7.3% of CytomX Therapeutics' outstanding common stock, based on 157,544,369 shares reported by the Issuer in its prospectus supplement dated May 12, 2025.
• LVPV is the record owner of all 11,538,461 shares.
• LCPV, as the general partner of LVPV, is deemed to beneficially own these shares.
• Patrick G. Enright and Juliet Tammenoms Bakker, as managing members of LCPV, are deemed to share voting, investment, and dispositive power over these securities.
• The filing is made under Rule 13d-1(b), signifying a passive investment intent, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable investment firm is generally viewed positively, indicating confidence in the company, although it does not provide operational or financial performance updates.

Positives

• The disclosure of a significant passive stake by a reputable investment firm like Longitude Capital may signal investor confidence in CytomX Therapeutics' long-term prospects.
• The investment firm's focus on healthcare and life sciences suggests a strategic alignment with CytomX's business, potentially attracting further institutional interest.

Risks

• The Reporting Persons disclaim beneficial ownership and group membership with Seven Fleet Advisors LLC, despite policies and procedures that might otherwise suggest such a group, which could be a point of legal nuance regarding beneficial ownership rules.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future financial performance or strategic direction.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology sector, specifically in companies like CytomX Therapeutics. Longitude Capital's investment aligns with broader trends of venture capital and private equity firms taking significant stakes in promising life sciences companies.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor like Longitude Capital may enhance investor confidence and potentially influence market perception of CytomX Therapeutics' stock.

Key Dates

Keywords

CytomX Therapeutics, Longitude Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Healthcare Investment, Passive Investment